Annual Meeting held in Chicago, IL, was host to a State of the Science session on novel diagnostics and therapeutics in renal cell and urothelial carcinomas. Dr. Michael Hofman presented an in-depth ...

An artificial intelligence-based tool identifies patients with high-risk, nonmetastatic prostate cancer (PCa) who would most likely benefit from treatment intensification, an investigator reported at ...

A new artificial intelligence (AI) test can identify which men with prostate cancer will benefit most from the life-extending ...

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

Former President Joe Biden said May 30 he is “optimistic” about the treatment plan for his Stage 4 prostate cancer, which ...

With a team of dedicated specialists, the New Mexico Cancer Center uses the latest technology, from blood tests and imaging ...

Form: Schedule a Call with a Patient Care Coordinator Proton therapy is an advanced treatment that sends radiation to the exact size, shape and depth of your tumor. It allows your physician to treat ...

Researchers used ArteraAI to identify 25% of prostate cancer patients in a large trial cohort for whom abiraterone halved the ...

has long been the backbone of treatment for metastatic prostate cancer. The male sex hormone testosterone (a type of hormone known as an androgen) is known to stimulate the growth of prostate ...

Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) said on Wednesday that the U.S. FDA has approved its blockbuster oral hormone blocker, ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a New Frontiers in Prostate-Specific Membrane ...